Danal 2025: Growth Continued, but the Nursing Tender and Earnings Quality Still Need Proof

Getting to Know the Company

Danal can sometimes look like a scattered services group. That is incomplete. In practice, this is a large labor-intensive platform built around four very clear engines: nursing services, special-needs frameworks, HR services, and medical services. In 2025 the group reached NIS 2.90 billion of revenue, NIS 201.2 million of operating profit, and NIS 121.0 million of net profit, with a market value of roughly NIS 2.7 billion in March 2026 and no controlling shareholder.

What is working now? The operating base is broad and resilient. Nursing remains the largest revenue engine, the Beit Ekstein special-populations activity keeps expanding, and medical services are benefiting from higher procedure volumes. On top of that, the group closed two loss-making activities in the fourth quarter, surrogacy and aesthetics, and entered 2026 with a cleaner tail.

What is still not clean? The first read of the bottom line is misleading. The jump to NIS 121 million of net profit does not reflect only a deep operating step-up. It also reflects the disappearance of three heavy items that distorted 2024: NIS 44.7 million of equity-accounted losses, a NIS 46.6 million fair-value hit on a convertible loan, and NIS 14.1 million of goodwill impairment. That means a surface read of the net-profit line can overstate the real underlying improvement.

That is the heart of the story. Danal is a better business than the 2024 headlines suggested, but not necessarily as strong as the 2025 net-profit surge implies. The active bottleneck now is not demand. It is visibility into the economics of the largest segment, nursing, just before a new tender that can reshape tariff levels and tariff structure. Above that sits a cash picture that is less generous than the headline of net cash surplus suggests.

The right filter for 2026 is straightforward: can Danal preserve nursing profitability, keep expanding special-populations activity without putting too much pressure on real-estate and wage costs, and bring HR back to growth that produces margin rather than volume alone. If those three things happen together, 2025 will look like a healthy reset year. If not, the group may simply have swapped old problems for newer regulatory and cash-quality ones.

Quick 2025 economic map:

Another important framing point: Danal looks diversified, but most of its revenue still comes from the public system. Public customers contributed NIS 2.46 billion in 2025, about 84.5% of total revenue, while the single largest customer, the National Insurance Institute, contributed NIS 1.4166 billion, or 48.8% of group revenue. This is a diversified platform by activity, but not a fully diversified platform by risk source.

The operating complexity also explains why Danal should not be read like a standard service company: 42 nursing branches, 12 HR branches, 34 housing frameworks, 28 schools, 7 employment centers, 14 operating rooms across four cities, and more than 32 thousand workers in the company presentation. The annual report details 4,288 direct employees plus about 29,250 caregivers excluded from the direct headcount. That creates scale advantages, but also makes the group highly sensitive to wages, staffing, regulation, and payment timing.

Events and Triggers

The first trigger: the new nursing tender. The NII tender was published in June 2024, moved through petitions, a court ruling in October 2025, an appeal in December 2025, and another clarification file in February 2026. The existing engagement was extended through the end of December 2026, with a one-year option or until winners are chosen, whichever comes first. That buys time, but it does not solve the economic question. If anything, it sharpens it. Danal explicitly warns that if the tender terms are not corrected, the tariff and tariff-structure changes could materially hurt nursing-segment profitability and, by extension, group profitability.

The second trigger: closing the loss-making activities. Surrogacy was stopped on December 31, 2025 after the Russia-Ukraine war intensified the operating difficulties and losses, and the remaining contracts are expected to wind down by June 2026. In addition, the aesthetics activity was shut in the fourth quarter, contributing to NIS 2.9 million of other expenses in 2025 and hurting fourth-quarter medical profitability. In the near term that creates noise. Over the medium term it cleans out activities that were not creating value.

The third trigger: the CEO transition. David Mizrahi announced his resignation in January 2026, and Oren Levy was appointed in March 2026 to take over on May 3, 2026. A management change is not the thesis by itself, but when it arrives right before a sensitive tender year and inside a broader strategic expansion program, it adds an execution layer that the market will watch quickly.

The fourth trigger: deepening the core rather than changing direction. At the end of 2024 the company prepared a three-year strategic plan focused on strengthening existing activities, expanding adjacencies, improving service and efficiency, and pursuing acquisitions. That already showed up in 2025 through more property purchases for special-populations activity, greater focus on managed services and foreign workers in HR, and after the balance sheet date, the acquisition of Avia Home in senior-community support services.

The fifth trigger: the war is still part of the picture, but it did not hit every engine equally. Nursing and special-populations activity remained close to full activity, while eye services and HR remain more exposed if fighting continues. That matters because it helps explain why some parts of the portfolio look defensive while others still carry near-term sensitivity.

Efficiency, Profitability and Competition

The 2025 paradox is that the business genuinely grew, but the quality of improvement was uneven. Revenue rose 5.3%, operating profit rose 8.2%, and net profit jumped to NIS 121.0 million. Yet net profit is not the right lens on its own. At the operating level, Danal ended the year with four different pictures: stable nursing, strong special populations, weaker HR margins, and medical growth with a messier fourth quarter.

What Actually Drove Profit

In nursing, revenue rose to NIS 1.552 billion and operating profit rose to NIS 99.5 million, with operating margin holding at 6.4%. That is a better number than it first appears, because the segment operates under ongoing caregiver shortages, wage pressure, and heavy regulation. The 42-branch national footprint creates scale and brand advantage, but that advantage matters far less if the economics of the tender shift against the company.

In special populations, the picture is cleaner. Revenue rose to NIS 616.2 million and operating profit increased to NIS 60.6 million, with margin improving to 9.8% from 9.5% a year earlier. The growth came mainly from higher occupancy in housing frameworks and the opening of new schools. This is also where Danal built support infrastructure during 2025: non-current assets increased by NIS 52.6 million, driven mainly by about NIS 56 million of real-estate purchases, most of them tied to housing activity.

In HR services, the top line was not enough. Revenue rose 5.6% to NIS 458.8 million, mainly on projects and foreign-worker activity in construction, but operating profit fell to NIS 23.1 million from NIS 30.3 million and margin fell to 5.0% from 7.0%. Management points to one-off client income in 2024, and that is fair, but it does not fully answer the question. Even in the fourth quarter of 2025, after all those explanations, operating profit was only NIS 5.1 million versus NIS 6.9 million a year earlier. So the business still has to prove that projects, outsourcing, and foreign-worker activity can rebuild margin, not just volume.

In medical services, the picture mixes growth with friction. Revenue rose 7.1% to NIS 262.6 million, mainly on higher procedure volumes, and operating profit rose to NIS 22.5 million. But the fourth quarter fell to NIS 4.1 million from NIS 6.9 million because the aesthetics shutdown sat on reported results. If one excludes shutdown costs, management’s presentation shows adjusted operating profit of NIS 25.8 million and a 9.8% margin, but that is not the reported number. It helps explain direction. It does not replace the audited base.

Where Competition Really Sits

Danal’s moat is not uniform. In nursing and special populations, the company benefits from scale, national footprint, operating know-how, licenses, heavy supervision, and deep links into public-service systems. Those are real entry barriers. In HR, by contrast, the company itself states that entry barriers are relatively low. The advantage there is one-stop-shop breadth, national reach, candidate databases, and reputation, but competition remains a competition of service quality and commercial terms, not a regulatory franchise.

Even in medical services, quality is not driven only by private demand. The Eye Group operates 14 operating rooms across four cities, with material dependence on agreements with HMOs and insurers. That makes it a real operating franchise, but not one that is detached from institutional-channel economics. Customer identity matters here: this is not just a retail LASIK story. It is also an institutional-contract story.

Cash Flow, Debt and Capital Structure

Danal’s operating cash flow is strong. It reached NIS 235.8 million in 2025, up from NIS 223.1 million in 2024. That matters because it shows the core business still generates cash. But if the goal is to understand real financial flexibility, the lens has to shift from operating cash flow alone to all-in cash flexibility, meaning how much cash actually remains after real uses.

Where Cash Was Built, and Where It Was Consumed

Operating cash flow of NIS 235.8 million sounds excellent. In practice, 2025 also included NIS 96.3 million of investment outflow and NIS 177.3 million of financing outflow, so cash ended the year lower at NIS 213.4 million versus NIS 251.2 million. The explanation is straightforward: NIS 86.3 million of CAPEX, NIS 4.9 million of intangible investment, NIS 6.5 million of advances for fixed assets, NIS 84.2 million of dividends including minorities, NIS 68.6 million of lease-principal repayment, and repayment of short and long debt.

That is the difference between a comfortable picture and a real one. The company presents net cash surplus of NIS 139.0 million at year-end 2025 versus NIS 136.8 million a year earlier. That math is correct, but it is correct only against loans and credit of NIS 74.4 million. It does not include lease liabilities of NIS 252.5 million. That means it does not describe the cash layer that is actually left to equity holders after the obligations of a platform built around branches, housing frameworks, medical centers, and leased vehicles.

Debt, Covenants and Balance-Sheet Structure

The good news is that the balance sheet is not under stress today. Equity rose to NIS 515.2 million, the equity ratio improved to 37.9% from 35.0%, and the company states that its borrowing subsidiaries comply with financial covenants. So this is not a story of covenant pressure or urgent refinancing.

The less comforting part is that the cash cushion is narrower than the balance-sheet headline suggests. Net working capital declined to NIS 123.8 million from NIS 141.8 million, and trade receivables plus long-term receivables increased by NIS 39.4 million. In HR, credit terms can stretch out to net plus 120 days, and medical institutional customers pay in 60 to 90 days. That is not unusual for this kind of business, but it does mean cash is working hard.

Outlook and What Comes Next

Right now, 2026 looks like a proof year, not a breakout year. To see why, start with five non-obvious findings:

• Finding one: the 2025 net-profit surge cleaned out noise, but it did not settle the question of earnings quality.
• Finding two: nursing stayed stable and profitable, but its 2027 economics are still open because of the tender.
• Finding three: special populations is the cleanest growth engine in the group, but it is also the one most dependent on real estate, occupancy, and funding rules.
• Finding four: HR has not yet returned to convincing operating leverage.
• Finding five: the cash picture is tighter than the net-cash headline suggests because leases and shareholder distributions consume a large part of the platform’s cash-generating power.

From here, the question is what has to happen over the next 2 to 4 quarters. At the top of the list sits the economics of nursing. Danal holds a meaningful share of the market, with about 12.9% of caregiver-based nursing services among the eligible population that does not receive the full benefit in cash, but that scale advantage matters less if the new tender compresses the economics per unit of activity. The test is not only whether Danal wins. It is under what terms it wins.

The second test is the quality of special-populations growth. In 2025 the segment proved it can grow through housing and new schools. But the Welfare Ministry is pushing policy toward community-based housing, and the company also faces a real bottleneck in locating suitable properties for new frameworks. That means demand is present, but the real bottleneck is operational and real-estate related rather than commercial.

The third test is HR. Backlog in the segment stood at NIS 207.3 million at the end of 2025 and declined to NIS 178.2 million by March 2026. That is still meaningful backlog, but not enough to ignore the 2025 margin compression. If the segment does not show margin recovery while continuing to grow projects and foreign-worker activity, the market may start to read it as a more cyclical volume engine and a less durable value engine.

The fourth test is medical services. Here the direction looks better. Core activity is growing, the Health Ministry continues to encourage HMOs to buy private surgical services, and the private market remains active. But this segment is more exposed to war conditions and consumer sensitivity, so the real signal will come from the quality of upcoming quarters after the aesthetics shutdown is fully cleared.

The right forecast line for Danal is this: the question is no longer whether the company knows how to grow. That part is already proven. The question now is whether it can grow while protecting unit economics, preserving acceptable all-in cash flexibility, and producing a profit structure that depends less on one-off cleanup. That is exactly what a proof year looks like.

Risks

The first risk is customer concentration and regulation. Nearly half of revenue comes from the NII, and another 24.1% comes from the Welfare and Education ministries combined. That is a stable revenue base, but it is also deep dependence on the state as the setter of tariffs, staffing rules, qualification rules, and audit processes. In Danal, stability and constraint come together.

The second risk is labor and wage pressure. Nursing faces ongoing caregiver shortages. In special populations, collective agreements, higher rent, food inflation, and general wage pressure all weigh on the cost line. This is a group that can pass some wage pressure through budget mechanisms, but not always at the same speed at which costs move in practice.

The third risk is that the group’s best growth engine depends on real estate. In special populations, the company needs suitable properties on long leases or ownership to open new frameworks. The more policy shifts toward community housing and the harder it becomes to locate appropriate sites, the more growth becomes a function of property availability rather than demand alone.

The fourth risk is that medical services and HR are more exposed to the broader economy and the war backdrop. The company itself highlights eye services and HR as areas that could be hurt more if fighting continues. That does not change the whole thesis, but it does change the mix of possible surprises in the next few quarters.

The fifth risk is over-reading the cash headline. Danal does not currently face a liquidity crisis. It has cash, acceptable equity, and covenant compliance. The risk is different: the market may focus on net cash surplus and ignore the fact that the group also pays a steady dividend, carries material lease obligations, and continues investing in property and infrastructure to support growth. This is not a survival risk. It is a capital-quality risk.

Short Sellers' Position

Short interest in Danal does not tell a story of an aggressive attack on the stock, but it is not complete indifference either. On March 27, 2026 short interest stood at 0.91% of float, with SIR at 3.11 days. That is low in absolute short-float terms, but materially above the sector average of 0.16%. The SIR is also elevated versus the sector.

The right read is mixed. The market is not building a deep collapse thesis here, but it is showing more scrutiny than one would expect for a seemingly defensive services name. That fits the core thesis well: the business is stable, but the regulatory layer and earnings quality still invite skepticism.

Conclusions

Danal ends 2025 with a stronger operating business and a cleaner strategic structure, but not with a simpler picture. What supports the thesis is a resilient demand base, a clear growth engine in special populations, an improving medical platform, and the cleanup of loss-making activities. The main blocker is that the largest engine, nursing, is moving into a sensitive tender year, while net profit still looks better than the true organic improvement and the all-in cash picture is narrower than it first appears. Over the short to medium term, the market is likely to focus mainly on tender economics, HR margin recovery, and whether growth can continue without compromising quality.

Current thesis: Danal is a quality services platform with real growth engines, but 2026 will decide whether 2025 marked the start of a higher-quality earnings base or mainly an accounting and strategic cleanup before a regulatory test.

What changed in this cycle is that the debate shifted from stability to earnings quality. In 2024 the problem was heavy noise. In 2025 the noise was cleared out, and that now makes it easier to see where the business is genuinely strong and where proof is still missing.

Counter-thesis: The market may be too harsh. If the nursing tender proves less damaging than feared, if HR returns to reasonable margins after the one-off distortions of 2024, and if medical services keep growing without the aesthetics tail, 2025 may later look like the beginning of a deeper improvement rather than a peak shaped by accounting cleanup.

What could change the market reading over the short to medium term is fairly clear: any update on the nursing-tender terms, quarters that show HR margins stabilizing, and continued special-populations growth without a worsening cost structure.

Why does this matter? Because with Danal the key question is not only how many services the group delivers. It is how much of that labor-intensive, regulation-shaped growth converts into durable earnings and cash that truly remain for shareholders after leases, CAPEX, and distributions.

Over the next 2 to 4 quarters, the thesis strengthens if Danal preserves nursing profitability, rebuilds HR margin, and keeps Beit Ekstein growing without a sharp worsening in real-estate and wage costs. It weakens if tender terms damage nursing economics, if HR keeps growing without matching margin, or if the all-in cash layer proves too tight for the group’s growth and payout ambitions.